Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you've been prescribed Wegovy and your pen says 1mg, you're at the third step of the titration ladder — past the starter doses, but not yet at the full maintenance level. The 1mg dose of semaglutide is a recognised milestone in the treatment journey, and understanding what changes at this point helps you know what to watch for. Wegovy is a prescription-only medicine; a clinician assesses whether it's right for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture the scene: your fourth injection is behind you, your prescriber has confirmed the next step, and you're holding a 1mg Wegovy pen. It's natural to wonder whether this is the dose that starts to feel different.
The honest answer is: often, yes. The 0.25mg and 0.5mg doses are largely about letting your gut adapt to semaglutide. At 1mg, the GLP-1 receptor agonist effect is more established. Semaglutide slows gastric emptying, signals the brain's appetite centres, and reduces the hormonal drive to eat. The clinical profile of semaglutide has been studied extensively, and 1mg sits at the point where most people begin to notice appetite and fullness shifting in a meaningful way, less urgency around meals, earlier satiety, smaller portions feeling sufficient.
That said, 1mg is still a stepping stone. The licensed maintenance dose for weight management is 2.4mg, and the NHS semaglutide guidance describes the full titration sequence clearly. You'll typically hold 1mg for four weeks before your prescriber considers whether 1.7mg is the right next move, and our guide to the 1.7mg Wegovy dose explains exactly what to expect when that conversation happens.
One thing worth knowing: some people feel a mild recurrence of nausea after moving up from 0.5mg. That's normal. It usually settles within a week or so, and staying hydrated, eating smaller meals slowly, and avoiding very fatty or spicy food tends to help more than people expect.
Gastrointestinal symptoms are the most frequently reported effects across the Wegovy dose range. At 1mg, the pattern is similar to earlier doses: nausea, loose stools, constipation, burping, and indigestion top the list. Headaches and fatigue are also reported, particularly in the days immediately following an injection.
Most of these settle as your body adjusts. The key distinction to hold in mind is between discomfort that fades and symptoms that demand attention. Severe, persistent stomach pain (especially if it radiates towards the back, with or without vomiting) needs urgent medical assessment. The MHRA's Drug Safety Update guidance on GLP-1 medicines highlights acute pancreatitis as a rare but serious risk; knowing the warning sign means you won't second-guess it if it happens.
Signs of an allergic reaction (swelling of the face or throat, difficulty breathing, rapid heartbeat) are also grounds for calling 999 or going to A&E. These are rare. The more common picture at 1mg is mild GI disruption that passes. If side effects are persistent or affecting your quality of life, speak to your prescriber, the titration pace can sometimes be adjusted.
You can report any suspected side effects directly to the MHRA via the Yellow Card scheme. That reporting matters; it feeds into ongoing safety monitoring for all medicines.
We hear this from patients regularly: the early weeks feel slow. You're measuring progress in small signs (a meal you didn't finish, an afternoon without snacking) rather than dramatic results. That's not failure. It's the titration working as it should.
The STEP 1 trial, published in the New England Journal of Medicine, found that semaglutide 2.4mg produced around 15% average weight reduction over 68 weeks. Reaching that maintenance dose (and giving it time to work) is the goal. The full Wegovy treatment overview covers the evidence behind the complete dose range.
What you do alongside the treatment matters too. Protein at each meal helps preserve muscle as weight shifts. Staying well-hydrated supports the GI side effects. Gentle strength-based activity, even walking, compounds the medicine's effect over time. None of this needs to be perfect at the 1mg stage; building habits gradually is more sustainable than overhauling everything at once. If you've been wondering whether Wegovy actually melts fat or works differently, that's a question our dedicated page answers in full.
For a detailed look at the transition that follows this point, the Wegovy 2 guide covers what changes as you move toward 1.7mg and beyond. And if you're curious how Wegovy pricing in the UK works across private providers, that's worth reading before your next order.
If you're not yet on treatment and want to understand whether Wegovy might be clinically suitable for you, our prescribers carry out a same-day clinical review, a real clinician reads your consultation answers, not software. Check your eligibility to get started.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.